Live Biotherapeutic Product GB104 Phase 1 Study in Colorectal Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 28, 2023

Primary Completion Date

December 22, 2023

Study Completion Date

December 22, 2023

Conditions

Solid TumorColorectal CancerSigmoid Colon CancerRectosigmoid Junction CancerCancerRectal Cancer

Interventions

DRUG

GB104(Level 1)

One capsule QD oral administration for 28 days

DRUG

GB104(Level 2)

Three capsules QD oral administration for 28 days

DRUG

GB104(Level 3)

Five capsules QD oral administration for 28 days

Trial Locations (1)

Samsung Medical Center, Seoul

All Listed Sponsors

lead

GILongevity

INDUSTRY

NCT05943041 - Live Biotherapeutic Product GB104 Phase 1 Study in Colorectal Cancer | Biotech Hunter | Biotech Hunter